Event Information:
Dates
From: 22 July, 2024
To: 26 July, 2024
Location
Munich, Germany (multiple locations)
Related Models
Infectious Disease Mouse Models (HIV, HBV), Humanized Mouse Models
TransCure BioServices at AIDS 2024: Advancing the Fight Against HIV
TransCure BioServices is thrilled to announce our participation in AIDS 2024, the 25th International AIDS Conference, taking place from July 22 to 26, 2024, in Munich, Germany, and virtually.
AIDS 2024 is expected to gather an estimated 15,000 participants from around the world, with the majority attending in person.
Join Dan Georgess, PhD, Chief Scientific Officer, at AIDS 2024 to discover our latest advancements in preclinical research models. Our innovative Humanized Immune System mouse models play a crucial role in the development of new treatments for HIV. Dan is eager to discuss potential collaborations and explore how our cutting-edge solutions can support ongoing and future HIV research projects.
AIDS 2024 will provide a powerful platform to align strategically around a unified and equitable response to the HIV pandemic, emphasizing an evidence-based approach that prioritizes people. In the lead-up to the conference, we are mobilizing support to champion this principle.
This conference is a must-attend event for anyone involved in HIV research and treatment. It offers a unique opportunity to expand your knowledge, present your latest research, and connect with global peers.
We look forward to welcoming you to Munich and uniting in the fight against HIV.
See you at AIDS 2024!
Presenting in person for TransCure bioServices:
Dan Georgess, PhD, Chief Scientific Officer
Dan is an innovative scientist with extensive international experience in team leadership, research strategy, and interdisciplinary collaboration. He is dedicated to promoting cross-functional efforts to address complex challenges in therapeutics development. Prior to joining TransCure bioServices, Dan was a Marie Curie Ph.D. fellow at ENS de Lyon (France), Suzan G. Komen postdoctoral fellow at the Johns Hopkins School of Medicine (USA), and assistant professor and leader of the Cancer Invasion and Metastasis Cluster at the Lebanese American University (Lebanon). In these roles, he developed cutting-edge in vivo and ex vivo approaches for hematopoiesis, autoimmunity, and cancer research, and co-authored 15 peer-reviewed publications. Since joining TransCure bioServices in 2022, initially as Project Leader then transitioning to Director of the Alliance Management Team and now CSO, Dan’s consistent focus has been to drive successful preclinical development of cell therapies and biologics for TransCure’s clients.